PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis
| Autor: | Claudia Augello, Monica Miozzo, Eleonora Bonaparte, Silvano Bosari, Rossella Falcone, Silvia Tabano, Dario Ricca, Agostino Cortelezzi, Alessandra Iurlo, Silvia M. Sirchia, Federica Savi, Antonina Parafioriti, Michele Ciboddo, Daniele Cattaneo, Nicola Stefano Fracchiolla, S. Lonati, Umberto Gianelli, Leda Paganini |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Cancer Research Pathology medicine.medical_specialty Stromal cell Basic fibroblast growth factor Biology Epigenesis Genetic chemistry.chemical_compound Transforming Growth Factor beta medicine Humans Epigenetics Myelofibrosis Myeloproliferative neoplasm PDGFB Hematology Proto-Oncogene Proteins c-sis DNA Methylation Middle Aged medicine.disease Prognosis Haematopoiesis medicine.anatomical_structure Long Interspersed Nucleotide Elements Oncology chemistry Primary Myelofibrosis Cancer research Female Fibroblast Growth Factor 2 Bone marrow Biomarkers |
| Zdroj: | Leukemia research. 39(2) |
| ISSN: | 1873-5835 |
| Popis: | Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterised by the clonal proliferation of the haematopoietic precursors together with the progressive development of bone marrow fibrosis. This stromal alteration is an important clinical issue and specific prognostic markers are not currently available. In bone marrow biopsies from 58 PMF patients, we explored the methylation pattern of genes encoding cytokines involved in the stromal reaction, namely platelet-derived growth factor-beta (PDGFB), transforming growth factor-beta (TGFB) and basic fibroblast growth factor (FGF2). We also evaluated the methylation profile of the Long Interspersed Nucleotide Element 1 (LINE-1). PDGFB, FGF2 and LINE-1, but not TGFB, were significantly differently methylated in PMF compared to controls. Significantly, PDGFB hypomethylation ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect